Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783069 | 1.00 | PRKCA (0.53) | PRKCAPTPN2HTR7KCNH2SIGMAR1 | |
| SCHEMBL3774921 | 0.88 | PRKCA (0.51) | PRKCAPTPN2HTR7KCNH2SIGMAR1 | |
| SCHEMBL3774923 | 0.88 | PRKCA (0.51) | PRKCAPTPN2HTR7KCNH2SIGMAR1 | |
| SCHEMBL15673462 | 0.87 | PRKCA (0.40) | PRKCAPTPN2HTR7KCNH2SIGMAR1 | |
| SCHEMBL30153039 | 0.77 | KCNH2 (0.71) | PRKCAPTPN2HTR7KCNH2CYP2D6 | |
| SCHEMBL1769593 | 0.74 | KCNH2 (0.70) | PRKCAPTPN2HTR7KCNH2CYP3A4 | |
| SCHEMBL6888447 | 0.74 | PRKCA (0.77) | PRKCAPTPN2HTR7KCNH2OPRM1 | |
| SCHEMBL6888816 | 0.73 | PRKCA (0.76) | PRKCAPTPN2HTR7KCNH2ALDH1A1 | |
| SCHEMBL1150254 | 0.73 | KCNH2 (0.55) | PRKCAPTPN2HTR7KCNH2TSHR | |
| SCHEMBL8034405 | 0.73 | PRKCA (0.55) | PRKCAPTPN2HTR7KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252151-B1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-05-14 | — | — | EP | claimed |
| US-8288409-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | claimed |
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | claimed |
| EP-2252151-B1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8288409-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, OPRL1 | PRKCA 1788/4885PTPN2 1645/4885HTR7 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.